Table 3.

Univariate analyses for OS and LC

	OS			LC
	HR	95% CI	p value	HR	95% CI	p value
Age (≥ median vs. < median)	1.22	0.57–2.60	0.605	0.58	0.15–1.84	0.357
Male vs. female	2.09	0.93–5.01	0.073	1.72	0.50–6.82	0.393
PS 0–1 vs. 2–3	1.06	0.49–2.40	0.884	0.80	0.25–2.76	0.717
T stage (T4a vs. T4b)	0.51	0.12–1.48	0.236	0*	0.59–0.59	0.014
N stage (N0 vs. N1)	0.82	0.32–1.86	0.649	0.43	0.06–1.81	0.267
M stage (M0 vs. M1)	0.71	0.33–1.53	0.276	0.26	0.07–0.89	0.032
Thyroidectomy vs. none	0.77	0.35–1.66	0.510	0.63	0.18–2.07	0.445
Chemotherapy vs. none	0.83	0.39–1.82	0.638	0.95	0.30–3.24	0.933
CRT vs. RT	0.73	0.34–1.57	0.417	1.07	0.34–3.66	0.909
Total dose (≥50 Gy vs. <50 Gy)	0.44	0.18–1.24	0.113	0.18	0.03–0.99	0.049
EQD2 (≥50 Gy vs. <50 Gy)	0.27	0.10–0.78	0.018	0.20	0.04–1.03	0.053
Hypofractionation vs. <5 Gy/fr	1.06	0.50–2.28	0.872	0.32	0.07–1.19	0.09

CI, confidence interval; CRT, chemoradiotherapy; EQD₂, equivalent dose in 2-Gy fractions; HR, hazard ratio; LC, local control; OS, overall survival; PS, performance status; RT, radiotherapy. * 1.1699 × 10^–9.